ATE228375T1 - THIOMOLYBDAT VERBUNDEN MIT MINDESTENS EINEM KOHLENHYDRAT, UND SEINE VERWENDUNG ZUR VORBEUGUNG UND BEHANDLUNG VON ERKRANKUNGEN, DIE DURCH EINE ANORMALE VASKULARISIERUNG GEKENNZEICHNET SIND, WIE Z.B. KREBS, ßFEUCHTEß MAKULADEGENERATION, RHEUMATOIDE ARTHRITIS - Google Patents

THIOMOLYBDAT VERBUNDEN MIT MINDESTENS EINEM KOHLENHYDRAT, UND SEINE VERWENDUNG ZUR VORBEUGUNG UND BEHANDLUNG VON ERKRANKUNGEN, DIE DURCH EINE ANORMALE VASKULARISIERUNG GEKENNZEICHNET SIND, WIE Z.B. KREBS, ßFEUCHTEß MAKULADEGENERATION, RHEUMATOIDE ARTHRITIS

Info

Publication number
ATE228375T1
ATE228375T1 AT99952903T AT99952903T ATE228375T1 AT E228375 T1 ATE228375 T1 AT E228375T1 AT 99952903 T AT99952903 T AT 99952903T AT 99952903 T AT99952903 T AT 99952903T AT E228375 T1 ATE228375 T1 AT E228375T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
cancer
thiomolybdate
carbohydrate
Prior art date
Application number
AT99952903T
Other languages
English (en)
Inventor
George Brewer
Sofia D Merajver
Dimitri Coucouvanis
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE228375T1 publication Critical patent/ATE228375T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99952903T 1998-09-04 1999-09-03 THIOMOLYBDAT VERBUNDEN MIT MINDESTENS EINEM KOHLENHYDRAT, UND SEINE VERWENDUNG ZUR VORBEUGUNG UND BEHANDLUNG VON ERKRANKUNGEN, DIE DURCH EINE ANORMALE VASKULARISIERUNG GEKENNZEICHNET SIND, WIE Z.B. KREBS, ßFEUCHTEß MAKULADEGENERATION, RHEUMATOIDE ARTHRITIS ATE228375T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9910398P 1998-09-04 1998-09-04
US10175998P 1998-09-25 1998-09-25
PCT/US1999/020374 WO2000013712A2 (en) 1998-09-04 1999-09-03 Methods and compositions for the prevention or treatment of cancer

Publications (1)

Publication Number Publication Date
ATE228375T1 true ATE228375T1 (de) 2002-12-15

Family

ID=26795562

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99952903T ATE228375T1 (de) 1998-09-04 1999-09-03 THIOMOLYBDAT VERBUNDEN MIT MINDESTENS EINEM KOHLENHYDRAT, UND SEINE VERWENDUNG ZUR VORBEUGUNG UND BEHANDLUNG VON ERKRANKUNGEN, DIE DURCH EINE ANORMALE VASKULARISIERUNG GEKENNZEICHNET SIND, WIE Z.B. KREBS, ßFEUCHTEß MAKULADEGENERATION, RHEUMATOIDE ARTHRITIS

Country Status (14)

Country Link
EP (1) EP1107795B1 (de)
JP (1) JP2002524426A (de)
KR (1) KR100702279B1 (de)
CN (1) CN100548383C (de)
AT (1) ATE228375T1 (de)
AU (1) AU773848B2 (de)
CA (1) CA2341752A1 (de)
DE (1) DE69904203T2 (de)
DK (1) DK1107795T3 (de)
ES (1) ES2188261T3 (de)
IL (1) IL141550A0 (de)
NZ (1) NZ510038A (de)
PT (1) PT1107795E (de)
WO (1) WO2000013712A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703050B1 (en) 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
EP1531827A4 (de) * 2002-05-24 2009-07-08 Univ Michigan Kupfer-verringernde behandlung für entzündliche und fibrotische erkrankungen
US20070292533A1 (en) * 2002-05-24 2007-12-20 Regents Of The University Of Michigan Copper lowering treatment of autoimmune diseases
GEP20074270B (en) 2002-07-23 2007-12-25 Univ Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
JP2007516234A (ja) * 2003-05-27 2007-06-21 アテニュオン，リミティド ライアビリティー カンパニー チオタングステン酸（塩）アナログ及びその使用
AU2005217623A1 (en) * 2004-02-24 2005-09-09 Attenuon Llp Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents
CA2675230A1 (en) * 2006-01-10 2008-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
WO2009009622A2 (en) * 2007-07-09 2009-01-15 Pipex Pharmaceuticals, Inc. Pharmaceutical compositions, including attm, and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
KR100972355B1 (ko) * 2008-05-08 2010-07-26 고려전자주식회사 순간식 가스보일러의 온수공급라인용 써모밸브조립체
GB201005394D0 (en) * 2010-03-30 2010-05-12 Magnus Intellectual Property Ltd Therapy
US10478455B2 (en) 2010-03-30 2019-11-19 Ucl Business Ltd Therapeutic use of tetrathiomolybdate
US20160220500A1 (en) * 2014-11-14 2016-08-04 Kent State University Targeting Intracellular Copper Ions for Inhibiting Angiogenesis Using Nanoparticles of Ternary Inorganic Metal Sulfide M1M2S4 (M1, independently, is Mg, Ca, Mn, Fe, or Zn; M2 = Mo or W) Compounds to Treat Metastatic Cancer
CN108634322A (zh) * 2018-05-16 2018-10-12 刘华 一种预防和调理癌症的方法
SG11202011680YA (en) * 2018-06-01 2020-12-30 Incyte Corp Dosing regimen for the treatment of pi3k related disorders

Also Published As

Publication number Publication date
CN1457261A (zh) 2003-11-19
DE69904203D1 (de) 2003-01-09
NZ510038A (en) 2003-10-31
AU773848B2 (en) 2004-06-10
JP2002524426A (ja) 2002-08-06
DK1107795T3 (da) 2003-03-24
WO2000013712A3 (en) 2000-09-28
AU6496099A (en) 2000-03-27
EP1107795B1 (de) 2002-11-27
DE69904203T2 (de) 2003-08-14
CA2341752A1 (en) 2000-03-16
CN100548383C (zh) 2009-10-14
IL141550A0 (en) 2002-03-10
WO2000013712A2 (en) 2000-03-16
PT1107795E (pt) 2003-04-30
ES2188261T3 (es) 2003-06-16
EP1107795A2 (de) 2001-06-20
KR100702279B1 (ko) 2007-04-02
KR20010082190A (ko) 2001-08-29

Similar Documents

Publication Publication Date Title
ATE228375T1 (de) THIOMOLYBDAT VERBUNDEN MIT MINDESTENS EINEM KOHLENHYDRAT, UND SEINE VERWENDUNG ZUR VORBEUGUNG UND BEHANDLUNG VON ERKRANKUNGEN, DIE DURCH EINE ANORMALE VASKULARISIERUNG GEKENNZEICHNET SIND, WIE Z.B. KREBS, ßFEUCHTEß MAKULADEGENERATION, RHEUMATOIDE ARTHRITIS
WO2005000901A3 (en) Cd20-specific antibodies and methods of employing same
SI2269656T1 (sl) Izbrana protitelesa, ki se veĹľejo na aminofosfolipide, in njihova uporaba v zdravljanju raka
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
HU9602169D0 (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
DE3482754D1 (de) Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung.
DE69902154D1 (de) Eisen-dextran verbindung zur verwendung als komponente in einer therapeutischen zusammensetzung zur behandlung oder prophylaxe von eisenmangel, sowie verfahren zur herstellung der eisen-dextran verbindung und ihre anwendung zur herstellung einer parenteral anwendbaren therapeutischen zubereitung.
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
Sokal Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment
WO2024178202A3 (en) Anti-cd3 antibodies and methods for their use
EP0281070A3 (de) Pharmazeutische Zusammensetzung für die Krebsbehandlung
WO2024191972A3 (en) Anti-lipocalin-2 antibodies and uses thereof
EP1401496A4 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
WO2003038130A3 (en) Therapeutics and diagnostics for disorders of erythropoiesis
ATE500269T1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
EP1234585A3 (de) Zusammensetzungen zur Vorbeugung oder Behandlung von Krebs
WO2020176461A3 (en) Methods and compositions for treating neuroendocrine prostate cancer
WO2024097660A3 (en) Monoclonal antibodies specific for fas ligand and uses thereof
ATE435284T1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
WO2004013303A3 (en) Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
BRPI0415420A (pt) igg3 úteis para estimular a fagocitose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1107795

Country of ref document: EP

REN Ceased due to non-payment of the annual fee